Patient Guide: Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • Get matched to the right study location for you
  • Connect directly with study coordinators at 8 participating sites
  • Understand eligibility with our simplified screening tool
  • Free service - we're here to help you access clinical research
Trial ID: NCTNCT06441747
Status: 🟢 Enrolling Now
Condition: Cholangiocarcinoma
Phase: PHASE2

Find a Study Location Near You

This study is available at 8 research sites. We'll help you connect with the location that's right for you.

Participating sites include:
  • Camperdown, New South Wales
  • Clayton, New South Wales
  • St Leonards, New South Wales
  • • And 5 more locations - let us help you find the closest one

Loading interactive enrollment tools...

The full interactive experience will load momentarily